228 related articles for article (PubMed ID: 15109810)
1. A revival of bispecific antibodies.
Kufer P; Lutterbüse R; Baeuerle PA
Trends Biotechnol; 2004 May; 22(5):238-44. PubMed ID: 15109810
[No Abstract] [Full Text] [Related]
2. Expression and purification of monospecific and bispecific recombinant antibody fragments derived from antibodies that block the CD80/CD86-CD28 costimulatory pathway.
Dincq S; Bosman F; Buyse MA; Degrieck R; Celis L; de Boer M; Van Doorsselaere V; Sablon E
Protein Expr Purif; 2001 Jun; 22(1):11-24. PubMed ID: 11388794
[TBL] [Abstract][Full Text] [Related]
3. Recombinant bispecific antibodies for cellular cancer immunotherapy.
Müller D; Kontermann RE
Curr Opin Mol Ther; 2007 Aug; 9(4):319-26. PubMed ID: 17694444
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic assessment of SEED: a new engineered antibody platform designed to generate mono- and bispecific antibodies.
Muda M; Gross AW; Dawson JP; He C; Kurosawa E; Schweickhardt R; Dugas M; Soloviev M; Bernhardt A; Fischer D; Wesolowski JS; Kelton C; Neuteboom B; Hock B
Protein Eng Des Sel; 2011 May; 24(5):447-54. PubMed ID: 21498564
[TBL] [Abstract][Full Text] [Related]
5. [Bispecific antibodies: what future?].
Pèlegrin A; Robert B
Med Sci (Paris); 2009 Dec; 25(12):1155-8. PubMed ID: 20035697
[TBL] [Abstract][Full Text] [Related]
6. Immunology. Two-in-one designer antibodies.
Parren PW; Burton DR
Science; 2009 Mar; 323(5921):1567-8. PubMed ID: 19299606
[No Abstract] [Full Text] [Related]
7. Smarter drugs: a focus on pan-specific monoclonal antibodies.
Fagète S; Fischer N
BioDrugs; 2011 Dec; 25(6):357-64. PubMed ID: 22050338
[TBL] [Abstract][Full Text] [Related]
8. Mitogenic properties of a bispecific single-chain Fv-Ig fusion generated from CD2-specific mAb to distinct epitopes.
Connelly RJ; Hayden MS; Scholler JK; Tsu TT; Dupont B; Ledbetter JA; Kanner SB
Int Immunol; 1998 Dec; 10(12):1863-72. PubMed ID: 9885907
[TBL] [Abstract][Full Text] [Related]
9. Variants of the antibody herceptin that interact with HER2 and VEGF at the antigen binding site.
Bostrom J; Yu SF; Kan D; Appleton BA; Lee CV; Billeci K; Man W; Peale F; Ross S; Wiesmann C; Fuh G
Science; 2009 Mar; 323(5921):1610-4. PubMed ID: 19299620
[TBL] [Abstract][Full Text] [Related]
10. Construction and characterization of a bispecific anti-CD20 antibody with potent antitumor activity against B-cell lymphoma.
Li B; Zhang X; Shi S; Zhao L; Zhang D; Qian W; Zheng L; Gao J; Wang H; Guo Y
Cancer Res; 2010 Aug; 70(15):6293-302. PubMed ID: 20631068
[TBL] [Abstract][Full Text] [Related]
11. A novel CD19-directed recombinant bispecific antibody derivative with enhanced immune effector functions for human leukemic cells.
Kellner C; Bruenke J; Stieglmaier J; Schwemmlein M; Schwenkert M; Singer H; Mentz K; Peipp M; Lang P; Oduncu F; Stockmeyer B; Fey GH
J Immunother; 2008; 31(9):871-84. PubMed ID: 18833000
[TBL] [Abstract][Full Text] [Related]
12. MT110: a novel bispecific single-chain antibody construct with high efficacy in eradicating established tumors.
Brischwein K; Schlereth B; Guller B; Steiger C; Wolf A; Lutterbuese R; Offner S; Locher M; Urbig T; Raum T; Kleindienst P; Wimberger P; Kimmig R; Fichtner I; Kufer P; Hofmeister R; da Silva AJ; Baeuerle PA
Mol Immunol; 2006 Mar; 43(8):1129-43. PubMed ID: 16139892
[TBL] [Abstract][Full Text] [Related]
13. Phage diabody repertoires for selection of large numbers of bispecific antibody fragments.
McGuinness BT; Walter G; FitzGerald K; Schuler P; Mahoney W; Duncan AR; Hoogenboom HR
Nat Biotechnol; 1996 Sep; 14(9):1149-54. PubMed ID: 9631069
[TBL] [Abstract][Full Text] [Related]
14. A recombinant bispecific single-chain fragment variable specific for HLA class II and Fc alpha RI (CD89) recruits polymorphonuclear neutrophils for efficient lysis of malignant B lymphoid cells.
Guettinger Y; Barbin K; Peipp M; Bruenke J; Dechant M; Horner H; Thierschmidt D; Valerius T; Repp R; Fey GH; Stockmeyer B
J Immunol; 2010 Feb; 184(3):1210-7. PubMed ID: 20042573
[TBL] [Abstract][Full Text] [Related]
15. Multivalency: the hallmark of antibodies used for optimization of tumor targeting by design.
Deyev SM; Lebedenko EN
Bioessays; 2008 Sep; 30(9):904-18. PubMed ID: 18693269
[TBL] [Abstract][Full Text] [Related]
16. Characterization of a novel bispecific antibody that mediates Fcgamma receptor type I-dependent killing of tumor-associated glycoprotein-72-expressing tumor cells.
Russoniello C; Somasundaram C; Schlom J; Deo YM; Keler T
Clin Cancer Res; 1998 Sep; 4(9):2237-43. PubMed ID: 9748144
[TBL] [Abstract][Full Text] [Related]
17. Cell surface receptors and bispecific monoclonal antibodies: the link between basic science and medical oncology.
Malavasi F; De Monte LB; Funaro A; Magrini E; Bonino LD; Momo M; Mariani M; Horenstein A; Natali PG
Year Immunol; 1993; 7():74-80. PubMed ID: 8396823
[No Abstract] [Full Text] [Related]
18. Fucose removal from complex-type oligosaccharide enhances the antibody-dependent cellular cytotoxicity of single-gene-encoded bispecific antibody comprising of two single-chain antibodies linked to the antibody constant region.
Natsume A; Wakitani M; Yamane-Ohnuki N; Shoji-Hosaka E; Niwa R; Uchida K; Satoh M; Shitara K
J Biochem; 2006 Sep; 140(3):359-68. PubMed ID: 16861252
[TBL] [Abstract][Full Text] [Related]
19. Immunoglobulin isotype knowledge and application to Fc engineering.
Brezski RJ; Georgiou G
Curr Opin Immunol; 2016 Jun; 40():62-9. PubMed ID: 27003675
[TBL] [Abstract][Full Text] [Related]
20. CD19-/CD3-bispecific antibody of the BiTE class is far superior to tandem diabody with respect to redirected tumor cell lysis.
Mølhøj M; Crommer S; Brischwein K; Rau D; Sriskandarajah M; Hoffmann P; Kufer P; Hofmeister R; Baeuerle PA
Mol Immunol; 2007 Mar; 44(8):1935-43. PubMed ID: 17083975
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]